Skip to main content

Statins at the end of life, revisited

The recently published statin-discontinuation trial  has been celebrated in the palliative care community.  It’s message is clear – go ahead and stop statins in patients nearing the end of life. 

Or is it?

I’ll offer a contrarian viewpoint: the trial does not reliably prove that people are helped by stopping statins in the final year or so of life. 

Why this “downer” message?  It’s because the study had insufficient power to assess if there are clinically meaningful differences between people who were randomized to stop their statin and those who were randomized to continue.  This is no fault of the investigators; the study was carefully planned and thoughtfully designed.   However, participants lived three times longer than expected (an average of 9 months, compared with a projected average of 3 months).  As a result, the original sample size projections and outcome analysis were jettisoned.  In consultation with the trial’s data safety and monitoring board, a new outcome of 60-day mortality was substituted. 

The results showed that 23.8% of people who stopped statins died within 60 days, compared with 20.3% who continued statins - a difference of 3.5%.   In other words, if you took 100 people nearing the end of life and stopped their statin, 3 ½ more of them would die because you stopped the statin than if you had continued statin therapy.  But, because the sample size of the study was relatively small (381), there is a lot of uncertainty in that estimate.  The true effect of discontinuing statins could be anywhere from causing 3 ½ fewer deaths to causing 10 ½ more deaths.   (This is based on the stated 90% confidence intervals of -3.5% to 10.5%) 

What does this mean in plain English?  Stopping statins may cause more people to die.  It may cause fewer people to die.  It may make no difference.  We just don’t know.   In contrast, it is incorrect to say that this trial proves that stopping statins has no effect on mortality.

Fortunately (or not), death is not the only outcome that’s important to people with advanced terminal disease.  The trial revealed some interesting findings around quality of life.  People who stopped statins had better “total” quality of life on a score-based measure.  However, the main factors that contributed to these better scores were perceptions of having better support and well-being, whereas physical and other elements of quality of life were no different.  Similarly, physical symptoms and performance status were similar between people who continued vs. stopped statins.   It’s hard to know what to make of these results; they are intriguing, but hardly an unequivocal endorsement for stopping statins.

This is not to say that statins are harmless.  Their side effects are well-documented, although the frequency of perhaps their most important side effect – a feeling of muscle aches and malaise – has been very difficult to pin down.  (These symptoms occur reasonably often, but in many if not most cases they are not due to statins).  There has also been concern that statins might worsen cognitive function by interfering with lipid metabolism in the brain.  Recent reviews  on this topic are reassuring, although statins in late life probably do not confer cognitive benefits either

Does the lack of a clear positive result from the statin discontinuation trial mean that we should continue statins for all people with advanced terminal illness?  Of course not.  This decision should be guided by the patient’s goals of care, their actual experience with and potential side effects from statins, and so forth.  Most studies do not provide an unequivocal answer to clinical questions, and this study is no different.  Yet, it does provide useful information that deepens our understanding of the potential benefits and harms of statins in this setting.  For that we should thank the investigators and all of the people who participated in the trial.

by: Mike Steinman

Comments

Jim Richardson said…
Thank you for expressing my thoughts exactly. Palliative care should be the exact opposite of the "one size fits all mentality." As a geriatrician as well as a palliative medicine practitioner, I'm all for stopping harmful or useless drugs, but these should be thoughtful, individualized decisions.
Ravi Ramaswamy said…
Excellent review and commentary on this recent interesting article, Mike. Thanks very much. One thing I will add is about the lack of evidence for the benefit of statins in older patients (>75 years), in whom we already base our clinical decisions on our beliefs and patient preferences. For "older patients" with advanced and life-limiting illness, this study may help with bolstering our discussions about discontinuing statins.
It's interesting that some of our "quality measures" evaluates our care based on statin use and LDL levels in these old-old patients with and without advanced illness.
kopiluwak nya said…
This comment has been removed by a blog administrator.

Popular posts from this blog

Geroscience and it's Impact on the Human Healthspan: A podcast with John Newman

Ok, I'll admit it. When I hear the phrase "the biology of aging" I'm mentally preparing myself to only understand about 5% of what the presenter is going to talk about (that's on a good day).  While I have words like telomeres, sirtuins, or senolytics memorized for the boards, I've never been able to see how this applies to my clinical practice as it always feels so theoretical.  Well, today that changed for me thanks to our podcast interview with John Newman, a "geroscientist" and geriatrician here at UCSF and at the Buck Institute for Research on Aging.

In this podcast, John breaks down what geroscience is and how it impacts how we think about many age-related conditions and diseases. For example, rather than thinking about multimorbidity as the random collection of multiple different clinical problems, we can see it as an expression of the fundamental mechanisms of aging. This means, that rather than treating individuals diseases, targeting …

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Length of Stay in Nursing Homes at the End of Life

One out of every four of us will die while residing in a nursing home. For most of us, that stay in a nursing home will be brief, although this may depend upon social and demographic variables like our gender, net worth, and marital status. These are the conclusions of an important new study published in JAGS by Kelly and colleagues (many of whom are geripal contributors, including Alex Smith and Ken Covinsky).

The study authors used data from the Health and Retirement Study (HRS) to describe the lengths of stay of older adults who resided in nursing homes at the end of life. What they found was that out of the 8,433 study participants who died between 1992 and 2006, 27.3% of resided in a nursing home prior to their death. Most of these patients (70%) actually died in the nursing home without being transferred to another setting like a hospital.

 The length of stay data were striking:

the median length of stay in a nursing home before death was 5 months the average length of stay was l…